A bill to limit US exposure to Chinese biotech firms has been introduced in the House and Senate.
BIOSECURE would cast a wide net, including by prohibiting the federal government from entering into contracts with US companies that do business with designated Chinese biotech firms.
The bill could find itself in the annual defense package as lawmakers negotiate a path forward.